Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Current Assets (2020 - 2025)

Lyell Immunopharma's Current Assets history spans 6 years, with the latest figure at $328.2 million for Q3 2025.

  • For Q3 2025, Current Assets fell 27.07% year-over-year to $328.2 million; the TTM value through Sep 2025 reached $328.2 million, down 27.07%, while the annual FY2024 figure was $379.6 million, 31.57% down from the prior year.
  • Current Assets for Q3 2025 was $328.2 million at Lyell Immunopharma, up from $282.2 million in the prior quarter.
  • Across five years, Current Assets topped out at $834.8 million in Q2 2021 and bottomed at $282.2 million in Q2 2025.
  • The 5-year median for Current Assets is $596.6 million (2023), against an average of $547.3 million.
  • The largest annual shift saw Current Assets increased 4.53% in 2022 before it crashed 43.54% in 2025.
  • A 5-year view of Current Assets shows it stood at $626.3 million in 2021, then rose by 3.99% to $651.3 million in 2022, then dropped by 14.83% to $554.7 million in 2023, then tumbled by 31.57% to $379.6 million in 2024, then fell by 13.54% to $328.2 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Current Assets are $328.2 million (Q3 2025), $282.2 million (Q2 2025), and $309.2 million (Q1 2025).